These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 30413818

  • 21. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S, Boschetti G, Cotte E, Cathey-Javouhay A, Laidet M, Chichery A, Francois Y, Glehen O, Flourié B.
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract] [Full Text] [Related]

  • 22. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
    Malesci A, Angelucci E, Bonifacio C, Sociale O, Omodei P, Repici A, Balzarini L, Danese S.
    Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
    [No Abstract] [Full Text] [Related]

  • 23. Pulmonary aspergillosis in a Crohn's disease patient receiving adalimumab and steroid therapy.
    Ferrer Bradley I, Maroto Arce N, Mora Escrig M, Hinojosa Del Val J.
    Gastroenterol Hepatol; 2019 Jun; 42(6):387-388. PubMed ID: 30042000
    [No Abstract] [Full Text] [Related]

  • 24. Occurrence of Sweet syndrome under anti-TNF.
    Banse C, Sobocinski V, Savoye G, Avenel G, Vittecoq O.
    Clin Rheumatol; 2015 Nov; 34(11):1993-4. PubMed ID: 26292633
    [Abstract] [Full Text] [Related]

  • 25. Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.
    Thompson G, Pepperell D, Lawrence I, McGettigan BD.
    BMJ Case Rep; 2017 Feb 22; 2017():. PubMed ID: 28228435
    [Abstract] [Full Text] [Related]

  • 26. [Adalimumab in Crohn's disease - data from real life].
    López San Román A, Van Domselaar M, Garrido E.
    Rev Esp Enferm Dig; 2008 Nov 22; 100(11):671-5. PubMed ID: 19159169
    [No Abstract] [Full Text] [Related]

  • 27. Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening.
    Debeuckelaere C, De Munter P, Van Bleyenbergh P, De Wever W, Van Assche G, Rutgeerts P, Vermeire S.
    J Crohns Colitis; 2014 Jun 22; 8(6):550-7. PubMed ID: 24295645
    [Abstract] [Full Text] [Related]

  • 28. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M, Beltrán B, Bastida G, Aguas M, Nos P.
    J Crohns Colitis; 2011 Apr 22; 5(2):157-61. PubMed ID: 21453886
    [Abstract] [Full Text] [Related]

  • 29. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.
    Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT.
    Clin Infect Dis; 2007 Dec 01; 45(11):1470-5. PubMed ID: 17990230
    [Abstract] [Full Text] [Related]

  • 30. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 31. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J, Kucharzik T.
    Z Gastroenterol; 2005 Jul 23; 43(7):689-90. PubMed ID: 16001352
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.
    J Crohns Colitis; 2014 Nov 23; 8(11):1454-63. PubMed ID: 24947334
    [Abstract] [Full Text] [Related]

  • 35. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB, Moss AC, Elias G, Nakao A.
    Inflamm Bowel Dis; 2010 May 23; 16(5):723-4. PubMed ID: 19728388
    [No Abstract] [Full Text] [Related]

  • 36. [Tuberculous liver abscess, anti-TNF alpha, and immune reconstitution inflammatory syndrome].
    Dussouillez G, Zayet S, Kone D, Royer PY, Toko-Tchuindzie L, Ruyer O, Gendrin V.
    Med Mal Infect; 2020 Feb 23; 50(1):90-91. PubMed ID: 31477453
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A, Bonnet D, Thebault S, Alric L.
    Gastroenterol Clin Biol; 2010 Sep 23; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract] [Full Text] [Related]

  • 40. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB, Sagynbaeva VÉ.
    Eksp Klin Gastroenterol; 2013 Sep 23; (7):18-22. PubMed ID: 24772870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.